Genomic gain at 6p21: a new cryptic molecular rearrangement in secondary myelodysplastic syndrome and acute myeloid leukemia

Leukemia
R La StarzaC Mecucci

Abstract

Fluorescence in situ hybridization and comparative genomic hybridization characterized 6p rearrangements in eight primary and in 10 secondary myeloid disorders (including one patient with Fanconi anemia) and found different molecular lesions in each group. In primary disorders, 6p abnormalities, isolated in six patients, were highly heterogeneous with different breakpoints along the 6p arm. Reciprocal translocations were found in seven. In the 10 patients with secondary acute myeloid leukemia/myelodysplastic syndrome (AML/MDS), the short arm of chromosome 6 was involved in unbalanced translocations in 7. The other three patients showed full or partial trisomy of the 6p arm, that is, i(6)(p10) (one patient) and dup(6)(p) (two patients). In 5/7 patients with unbalanced translocations, DNA sequences were overrepresented at band 6p21 as either cryptic duplications (three patients) or cryptic low-copy gains (two patients). In the eight patients with cytogenetic or cryptic 6p gains, we identified a common overrepresented region extending for 5-6 megabases from the TNF gene to the ETV-7 gene. 6p abnormalities were isolated karyotype changes in four patients. Consequently, in secondary AML/MDS, we hypothesize that 6p gains are major pa...Continue Reading

References

Jul 1, 1991·European Journal of Haematology·B JohanssonF Mitelman
Mar 1, 1990·Cancer Genetics and Cytogenetics·A K JacobA A Sandberg
Apr 1, 1988·Cancer Genetics and Cytogenetics·C MecucciH Van den Berghe
Jan 1, 1995·Cytogenetics and Cell Genetics·M HöglundN Mandahl
Nov 5, 1997·Nature Genetics·S IidaR Dalla-Favera
Oct 20, 1999·Cancer Genetics and Cytogenetics·K S SornbergerC C Morton
Jan 31, 2002·Trends in Genetics : TIG·Paweł Stankiewicz, James R Lupski
Jul 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Giuseppe SaglioMariano Rocchi
Aug 10, 2002·Science·Jeffrey A BaileyEvan E Eichler
Nov 7, 2003·Genes, Chromosomes & Cancer·Ching C LauPulivarthi H Rao

❮ Previous
Next ❯

Citations

Mar 23, 2010·Cancer Genetics and Cytogenetics·Maria KarakostaKalliopi N Manola
Aug 13, 2013·Journal of Proteomics·C H BorchersUNKNOWN Human Proteome Organization Chromosome 6 Consortium
Sep 14, 2017·Journal of Pediatric Hematology/oncology·Sarah B WhittleAndras Heczey
Feb 2, 2010·American Journal of Respiratory Cell and Molecular Biology·Nicole CarpeFeige Kaplan

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.